Ibrutinib and venetoclax continue to provide benefits for patients with chronic CLL and SLL

Lower levels of inflammatory markers and tumour burden is linked to improvements in PFS with Ide-Cel in R/R multiple myeloma

Combination of zanubrutinib and venetoclax shows promise in high-risk TN CLL/SLL with del(17p) and/or TP53 mutation

Isatuximab in combination with pomalidomide and dexamethasone shows promising efficacy in 2nd line RRMM

Encouraging results using mismatched unrelated donors in stem cell transplantation

Importance of MRD in newly developed multiple myeloma

Teclistamab continues to demonstrate deep and durable responses in relapsed/refractory multiple myeloma

Isatuximab shows benefit in transplant-ineligible patients with newly diagnosed multiple myeloma

ASCO 2024: Two studies report on isatuximab combos in transplant-ineligible patients with newly diagnosed multiple myeloma

Immune therapy with belantamab mafodotin and elotuzumab shows encouraging safety profile and preliminary efficacy in RRMM

Manageable safety profile with early efficacy of Tec-DR in NDMM

Daratumumab plus bortezomib/lenalidomide/dexamethasone in transplant-eligible patients with NDMM: MRD analysis